Alterity Therapeutics Limited (ATHE)
| Previous close | 1.6000 |
| Open | 1.6100 |
| Bid | 1.5600 x 100 |
| Ask | 1.6400 x 100 |
| Day's range | 1.5700 - 1.6100 |
| 52-week range | 1.5500 - 5.4100 |
| Volume | |
| Avg. volume | 38,593 |
| Market cap | 14.257M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireAlterity Therapeutics to Present at MST Financial Webinar
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data fo
ZacksAlterity (ATHE) Up on Interim Data From Advance MSA Study
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
- GlobeNewswire
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to develo
